{"nct_id":"NCT06921785","title":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-05-06","start_date_type":"ACTUAL","primary_completion_date":"2029-03-16","primary_completion_date_type":"ESTIMATED","completion_date":"2030-03-14","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}